DOI: 10.1007/s11306-018-1365-5
Fecha: 9 Mayo 2018
Revista: Metabolomics
Autores: J. C. Martínez-Ávila, A. García Bartolomé, I. García, I. Dapía, Hoi Y. Tong, L. Díaz, P. Guerra, J. Frías, A. J. Carcás Sansuan, A. M. Borobia
Zonisamide is a new-generation anticonvulsant antiepileptic drug metabolized primarily in the liver, with subsequent elimination via the renal route.
Objectives: Our objective was to evaluate the utility of pharmacometabolomics in the detection of zonisamide metabolites that could be related to its disposition and therefore, to its efficacy and toxicity.
